Analysts Lift Harmony Biosciences’ 2026 EPS to $4.00 While Shares Drop 7.8%
Analysts raised Harmony Biosciences’ 2026 EPS estimates from $3.72 to $4.00 over the past 60 days, reflecting an improved financial outlook. However, shares have declined 7.8% over six months as the company posted mixed earnings results in two of the last four quarters, with a 7.2% average surprise.
1. EPS Estimate Revision
Consensus estimates for Harmony Biosciences’ fiscal 2026 EPS rose from $3.72 to $4.00 over the past 60 days, reflecting analysts’ more optimistic projections for the company’s upcoming financial performance.
2. Share Price Performance
Despite the upgraded earnings outlook, HRMY shares have fallen 7.8% over the last six months, underperforming broader biotech peers as investors weighed mixed operational results against improving estimates.
3. Quarterly Surprise History
In the trailing four quarters, Harmony Biosciences beat EPS estimates twice and missed twice, delivering an average earnings surprise of 7.2%, indicating volatility in execution relative to expectations.
4. Analyst Outlook
The EPS upgrade signals confidence in future profitability, but the pattern of mixed quarterly results and recent share decline suggests investors remain cautious about near‐term revenue drivers and commercialization progress.